Skip to content

Site Navigation

Exclusive Sponsored

PB Conference Learning Gallery

Search AI Powered

Human content, AI powered search.

Latest Stories

Start your day right!

Get the latest updates and insights delivered to your inbox

Enter your email

Exclusive Sponsored

PB Conference Learning Gallery

Advertise With Us Terms & Conditions Privacy Policy Cookie Policy Contact About Us Newsletter Subsciption Subscribe

Follow us

Home
fulvestrant combination therapy

fulvestrant combination therapy

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Longjam Dineshwori

Apr 11, 2025

Recent

load more

Advertise With Us Terms & Conditions Privacy Policy Cookie Policy Contact About Us Newsletter Subsciption Subscribe

© Copyright 2025 Garavi Gujarat Publications Ltd & Garavi Gujarat Publications USA Inc